CD10MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features

Kennosuke Karube, Ying Guo, Junji Suzumiya, Yasuo Sugita, Yuko Nomura, Kohei Yamamoto, Kei Shimizu, Shirou Yoshida, Hideki Komatani, Morishige Takeshita, Masahiro Kikuchi, Naoya Nakamura, Osamu Takasu, Fumiko Arakawa, Hiroyuki Tagawa, Masao Seto and Koichi Ohshima

Data supplements

Article Figures & Data


  • Figure 1

    Pathological features of CD10MUM1+ follicular lymphoma. In H&E sections, the lymphoma cells form definite follicular structures (A). The follicular structures are confirmed by follicular dendritic cell (FDC) meshwork stained for CD21 (B). In this case, almost all lymphoma cells are large cells and their proliferation shows a “sheet-like” pattern (E). This patient was diagnosed as grade 3B. Lymphoma cells are positive for CD20 (C) and MUM1 (D,F). All figures are from patient 7. Original magnification: (A-D) × 10, (E-F) × 100. Images were visualized using an Olympus AX80 microscope (Olympus, Tokyo, Japan), equipped with (A-D) an Olympus Planapo 4×/0.16 numerical aperture (NA) objective or (E-F) an Olympus Planapo 40×/0.95 NA objective. Images were captured using an Olympus DP70 camera and Olympus DP controller software, and were processed using Olympus DP manager software.


  • Table 1

    Comparison between CD10MUM1+ and CD10+MUM1 follicular lymphomas

    FeaturesCD10MUM1+ FLCD10+MUM1 FLP
    Pathological features
        All patients, n22119
            Grade 3A/B, %91 (20/22)17 (20/119)< .001*
            With diffuse area, %59 (13/22)19 (23/119)< .001*
            Bcl2 expression, %59 (13/22)93.7 (112/119)< .001*
            Bcl6 expression, %54 (12/22)72 (86/119).1*
            BCL2 translocation, %5 (1/20)92.5 (110/119)< .001*
            BCL6 translocation, %30 (6/20)4.2 (5/119)< .001*
            BCL6 amplification, %62 (10/16)26 (6/23)< .05*
        Only patients of grade 3A/B, n2020 + 23
            With diffuse area, %55 (11/20)45 (9/20).44*
            Bcl2 expression, %60 (12/20)80 (16/20).17*
            Bcl6 expression, %52 (11/21)70 (14/20).24*
            BCL2 translocation, %5.3 (1/19)60 (12/20)< .001*
            BCL6 translocation, %32 (6/19)16 (7/43).17*
            BCL6 amplification, %62 (10/16)26 (6/23)< .05*
    Clinical features
        All patients, n22129
            Sex, no. male:female16:653:66< .01*
            Age, y67.058.7< .001§
            B symptoms, no. +:−5:1216:88.16*
            No. stage I + II:III + IV12:1057:57.70*
            LDH level, U/I423428.44§
        Only patients of grade 3A/B, n2025
            Sex, no. male:female15:516:9.43*
            Age, y65.357.4< .01§
            B symptoms, no. +:−5:126:13.94*
            No. stage I + II:III + IV10:1013:8.44*
            LDH level, U/I496740.41§
    • Values in parentheses indicate no. of patients out of the total evaluable.

    • * χ2 test.

    • One patient showed both BCL6 gene translocation and amplification.

    • Twenty-three patients of CD10+MUM1FL (grade 3) were added to previous patients for analysis of BCL6 gene abnormality.

    • § t test.